Pr3vent: Revolutionizing Newborn Eye Screening with Machine Learning

The ML-powered eye screening solution provided by Pr3vent has revolutionized the way newborn eye screening is conducted. The solution has not only made the process more efficient but also more accurate. With the ability to detect pathology in a newborn’s retina and fundus images with high accuracy, the solution is ready for FDA approval. If approved, Pr3vent’s solution could scale newborn screening in the United States and globally. By reducing cost per screening by 10x and by scaling ophthalmologists’ expertise through automation, it makes timely eye screening accessible to no less than 4 million babies in the US alone. This means that ophthalmologists can now focus on patients who require immediate assistance, instead of looking through dozens of normal images of healthy individuals. Given that up to 97% of eye conditions can be treated in the first few months of life, Pr3vent may significantly reduce the number of infants and adults suffering from vision impairment and vision loss.

Achieved an accuracy of ~96% in detecting pathology in newborn eye retina

Achieved a 10x reduction in cost per screening

Made eye screening accessible to more than 4M infants in the US alone